João Hamilton Romaldini

João Hamilton Romaldini

Auto-generated profile, based on publicly available information

João Hamilton Romaldini

Pontifícia Universidade Católica de Campinas, Campinas, Brasil

Research Focus & Metrics

Academic Career Length

55Years (1972-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 1983 in The Journal of Clinical Endocrinology & Metabolism
Verified
Journal Article
Closed access
PDF file
JRJoão H. Romaldini
João H. Romaldini
NBNazareth Bromberg
Nazareth Bromberg
RWRubens S. Werner
Rubens S. Werner
LTLidia M. Tanaka
Lidia M. Tanaka
MWMarisa C. Werner
Marisa C. Werner
LRLuiz C. F. Reis
Luiz C. F. Reis
We compared the effects of high and low dosages of antithyroid drugs in 113 patients with Graves’ hyperthyroidism. The patients were randomly divided into 2 groups. In group A, 65 patients received either methimazole (MMI): 60 ± 14.5 mg/day (mean ± sd); range 40–100 mg/day, or propylthiouracil (PTU): 693 ± 173 mg/day; range 500–1200 mg/day. These high doses were maintained throughout treatment with later addition of 50–75 μg T3 daily. Forty eight patients (group B) were treated with lower doses of MMI or PTU without thyroid hormone addition. The maintenance dose of MMI was 13.6 ± 7 mg/day (range 5–25 mg/day) and that of PTU was 180 ± 58 mg/day (range 100-300 mg/day). The treatment period was 15.1 ± 4.2 (range 10–30) months for group A and 13.5 ± 2.2 (range 12–20) months for group B. Remission occurred in 75.4% patients from group A and in 41.6% patients from group B (P < 0.001). The mean follow-up was 42 ± 14 months (17–81 months). The free T4 index (FT4I) in group A remained below the normal range during treatment. The mean FT4I, obtained during the course of treatment, of patients who went into remission from group A was significantly (P < 0.001) lower than in relapsed patients (4.8 vs. 6.5). Moreover, there was an inverse correlation between mean FT4 and maintenance daily dose of either MMI (r = −0.567; P < 0.001), or PTU (r = −0.379; P < 0.01). A fall in microsomal antibody (MCHA) titer occurred mainly in remission patients, and was more significant (P < 0.05) in group A patients. In contrast, 11 (7 from group B) of the 16 patients with an increase of micro-somal antibody levels relapsed. The frequency of negative tests of thyroid-stimulating antibody was higher in group A patients (71%) than in group B (29%) at the end of therapy (P < 0.01). No correlation was found between thyroid T3 suppressibility and either mean FT4I or thyroid-stimulatory antibody activity during treatment. Our findings show that patients treated with high doses of PTU or MMI throughout treatment have a higher remission rate when compared to those treated with a more conventional regimen. These results support the hypothesis that large antithyroid drug doses may have greater immunosuppressive effects than low dosage regimens. Furthermore, a high dosage regimen could permit the restoration of the immune surveillance mechanisms and, thus, lasting remission of Graves’ disease.

1 April 2003 in The Journal of Clinical Endocrinology & Metabolism
Verified
Journal Article
Closed access
JSJose Sgarbi
Jose Sgarbi
FVFábio G. Villaça
Fábio G. Villaça
BGBenito Garbeline
Benito Garbeline
HVHeloísa E. Villar
Heloísa E. Villar
JRJoão H. Romaldini
João H. Romaldini
Subclinical hyperthyroidism has been associated with harmful cardiac effects, but its treatment remains controversial. This study was designed to assess the cardiac effects of the normalization of serum TSH concentration in patients with endogenous subclinical hyperthyroidism. Ten patients (median age, 59 yr; range, 16-72 yr) with normal serum free T(4) and free T(3) concentration and a stable suppression of serum TSH levels were evaluated by Doppler-echocardiography, by standard and 24-h electrocardiography monitoring (Holter), and by the clinical Wayne index. Ten subjects, matched for age and sex, were used as controls. Patients were reevaluated 6 months after achieving stabilized euthyroidism by using methimazole with a median initial dose of 20 mg daily (10-30 mg daily). After reaching euthyroidism, we found a significant decrease in the heart rate (P = 0.008), the total number of beats during 24 h (P = 0.004), and the number of atrial (P = 0.002) and ventricular (P = 0.003) premature beats. Echocardiographical data resulted in a reduction of the left ventricular mass index (P = 0.009), interventricular septum thickness (P = 0.008), and left ventricular posterior wall thickness (P = 0.004) at diastole. Furthermore, the early diastolic peak flow velocity deceleration rate was significantly higher (P = 0.02) in the untreated patients compared with controls. The Wayne clinical index was higher in patients than in controls (P = 0.001) and decreased after treatment (P = 0.004). Serum TSH concentration returned to normal values after 2.5 months (range, 1.0-7.0 months) on methimazole therapy (0.05 vs. 1.42 mU/liter; P = 0.002). Serum free T(4) values were normal in patients before treatment but significantly decreased after reaching the euthyroidism (16.9 vs. 11.5 pmol/liter; P = 0.002). In contrast, serum free T(3) concentration did not differ among the groups. In conclusion, our findings support that early antithyroid therapy should be considered in patients with endogenous subclinical hyperthyroidism, where it is needed to prevent potential progression to a more advanced heart disease.

1 January 2007 in Archives of Gerontology and Geriatrics
Verified
Journal Article
Closed access
VCValéria B. Chueire
Valéria B. Chueire
JRJoão H. Romaldini
João H. Romaldini
LWLaura Sterian Ward
Laura Sterian Ward

1 December 2015 in Thyroid®
Verified
Journal Article
Closed access
DVDanilo Villagelin
Danilo Villagelin
JRJoão H. Romaldini
João H. Romaldini
RSRoberto B. Santos
Roberto B. Santos
AMAna B.B.P. Milkos
Ana B.B.P. Milkos
LWLaura S. Ward
Laura S. Ward
Background: Low doses of antithyroid drugs (ATD) for extended periods may be an alternative for Graves' disease (GD) patients who relapse after a course of ATD. Methods: Patients with GD relapse ( n = 238) after discontinuation of ATD therapy for 12–24 months were retrospectively analyzed in a nonrandomized study. Radioiodine (RAI) treatment and L-thyroxine replacement was used in 114 patients, and a low dose of methimazole (MMI; 2.5–7 mg/daily) was used in 124 patients. Thyroid dysfunction, Graves' ophthalmopathy (GO) evolution, quality of life (QoL), and body weight were evaluated during the follow-up. Results: The mean follow-up was 80.8 ± 35.3 months for the RAI group, and 71.3 ± 40.3 months for the low-dose MMI group. No notable side effects were observed in either group. Thyroid dysfunction was predominant in the RAI group ( p < 0.001), and euthyroidism was more common in the MMI group ( p < 0.001). GO deterioration was mainly evaluated by clinical activity score (CAS)—it was higher in the RAI group ( p < 0.0005) over all periods of follow-up. Multivariate logistic analysis showed that RAI treatment was associated with no improvement in CAS during follow-up (24 months: OR = 3.51 [CI 1.02–12.03], p < 0.05; 36 months: OR = 8.46 [CI 1.47–48.58], p < 0.05; 48 months: OR = 19.52 [CI 1.70–223.10], p < 0.05; 60 months: OR = 21.1 [CI 1.5–298], p < 0.05). Kaplan–Meier survival analysis confirmed this finding ( p < 0.0003). Assessment of QoL using the Short Form Health Survey's 36 parameters in stable euthyroid patients (at least six months) was similar in both groups. The RAI group patients gained more weight ( p < 0.005), particularly after 24 months of follow-up. Conclusions: The use of low doses of MMI is efficient and safe, and offers better outcomes for GO than RAI treatment. Prolonged low doses of MMI may be an alternative choice for relapsed GD patients, particularly for GO patients or for patients who refuse a definitive treatment.

1 April 1989 in The American Journal of the Medical Sciences
Verified
Journal Article
Open access
MWMarisa C. Werner
Marisa C. Werner
JRJoão H. Romaldini
João H. Romaldini
NBNazareth Bromberg
Nazareth Bromberg
RWRubens S. Werner
Rubens S. Werner
CFChady S. Farah
Chady S. Farah
The authors studied 389 Graves’ hyperthyroid patients receiving either high propylthiouracil (PTU) or methimazole (MMI) daily doses or low doses to evaluate whether adverse effects were related to the thionamide drugs or its daily dose regimen. Group 1 patients (n = 286) received high PTU (728 ±216 mg/day, n = 92) or MMI (60 ± 19 mg/day, n = 94) doses, and group 2 patients (n = 103) were treated with low PTU (255 ± 85 mg/day, n = 39) or MMI (23 ± 10 mg/day, n = 64) doses. Major adverse effects were observed in 11 (2.8%) patients. Of these, four (1.0%) had agranulocytosis, two (0.5%) were granulocytopenic and five (1.3%) had hepatotoxicity. Agranulocytosis occurred in two patients from each group, 0.7% and 1.9%, respectively from group 1 and group 2. There was no significant difference between the groups or the types of thionamide. There also was no correlation with the patients’ age. All of the patients were hyperthyroid, and its onset occurred in the first to third month of treatment. Full recovery was achieved in all cases after drug withdrawal. Four of 5 patients with hepatotoxicity were treated with high PTU doses, and one patient received low MMI doses (p <.05). All patients were euthyroid. Arthralgias, skin rash and gastric intolerance, the minor adverse effects of thionamides studied, were observed in 52 (13.4%) of the patients. Although no significant differences were found, most of the patients experiencing side effects were from group 1 an received MMI therapy. These adverse effects did not demand drug withdrawal. The present study showed that adverse effects of thionamide drugs were similar in both highand low-dose regimens. These undesirable effects demand a strict follow-up, and the high dose regimen for Graves’ disease treatment is advised for patients with particularly severe symptoms.

1 July 2004 in Thyroid®
Verified
Journal Article
Closed access
RSRoberto B. Santos
Roberto B. Santos
JRJoão H. Romaldini
João H. Romaldini
LWLaura S. Ward
Laura S. Ward
In order to assess the effect of propylthiouracil (PTU) or methimazole (MMI) pretreatment on patient outcome after radioiodine therapy, we examined 100 patients with Graves' disease 3, 6, 9, and 12 months after administration of a 10-mCi standard single dose of 131I. They were assigned to one of three groups: no drug (ND) treatment (30 cases); MMI (45 cases); and PTU (25 cases). Antithyroid drugs (ATD) were withdrawn 15 days before radioiodine administration. The groups were similar concerning age, gender, ATD pretreatment duration, goiter size, and initial serum triiodothyronine (T3), thyroxine (T4), free thyroxine (FT4), antithyroid autoantibody levels, 24-hour radioiodine uptake and 131I dose administered per gram of thyroid tissue. ND and MMI groups presented a similar rate of cure of 73.3% and 77.8% respectively (p = NS). In contrast, the PTU group showed a rate of cure of only 32% (p < 0.05). Logistic regression analysis indicated that PTU administration (p = 0.003) and thyroid size (p = 0.02) were the variables related to radioiodine therapy failure. Our data demonstrate that the chance of 131I treatment failure is higher in individuals using PTU than in patients using MMI or not using any ATD before radioiodine (odds ratio [OR] 5.84; 95% confidence interval [CI] 1.82–18.76) suggesting that PTU should be avoided in the treatment of patients with Graves' disease.